Group items tagged

In a recent interview with The Telegraph, health secretary Steve Barclay stated that he has asked his officials within DHSC to look at a "pharmacy first" approach to alleviate pressures on A&E departments in order to avoid the widely predicted NHS winter crisis. On the face of it, this a welcome if long overdue recognition that community pharmacy is an essential part of our national healthcare infrastructure alongside our GP and A&E colleagues. But let's not get carried away - we have had lots of praise from politicians in the past which have not then been backed by firm commitments for a sustainable future for the network. Could this be a turning point? I hope so, but I am not confident it will be. I fear this may turn out to be another emergency stop-gap measure which does nothing to secure the long-term viability of the sector in England. The role of community pharmacy during the recent Covid pandemic demonstrated clearly how important we are to ensure people have easy access to essential healthcare support, advice and services. The NHS winter crisis can only be avoided or at least mitigated if the potential of the community pharmacy network to provide more patient care services is unlocked and that Barclay requires you to end pharmacy funding austerity and start investing. The Treasury will no doubt say there is no more money, but what then the alternative other than a NHS winter crisis? And, of course, treating people in secondary care settings is far more costly than community pharmacy based interventions.

The National Pharmacy Association (NPA) has announced that the Chief Pharmaceutical Officer for England, David Webb will be among the keynote speakers at the Pharmacy Odyssey Conference on 13 October. He and other special guests will discuss the future of community pharmacy within the NHS, during a day of insight and practical advice for pharmacy teams. The NPA promises expert opinion on the current pressures in the sector and a thorough exploration of the long-term picture. NPA Director of Membership, Simon Tebbutt, explains: "With the NPA centenary in 2021 behind us, this will be a foray into the future - mapping the coming decade, and next half-century - as well as covering the many challenges of the present time." The theme of the conference, to be held online and sponsored by Novo Nordisk, is Pharmacy Odyssey: Services, Supply and Sustainability.

The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors. "Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant Gastroenterologist at NHS Greater Glasgow and Clyde. "Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year. The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their condition." The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for upadacitinib in UC in July 2022.

The opinions of pharmacists on the ketogenic diet can vary greatly. Some believe that it is a potentially effective and safe way to lose weight, while others are more skeptical about its ability to promote sustainable health benefits over the long term. Ultimately, the success of the ketogenic diet will depend on each individual's unique circumstances and personal goals, so it is important to consult with a medical professional before making any major changes to your diet or lifestyle. 1. KETO DIET IS CONSIDERED A GOOD WAY TO LOSE WEIGHT Some people find that the ketogenic diet can boost their energy levels and help them lose weight quickly, while others feel that they are more easily able to stick to this diet as it allows them to eat a wider variety of foods. Many people find that the ketogenic way of eating prevents cravings and helps them avoid unhealthy food choices, which can be an important factor in weight loss success. So if you are starting your ketogenic diet journey, it is important to seek out the advice of a medical professional who can help you create an individualized plan that will support your specific goals. It's also important to track your progress regularly and monitor how you are feeling so that you can make any necessary adjustments along the way.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire. The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters. LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee wellbeing. This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people living with skin conditions, their families and society.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

Immunogenicity refers to the capacity of a vaccine to provoke an immune response in the body. An effective immune response is characterized by the production of specific antibodies, activation of immune cells, and the development of immunological memory. The goal is to elicit a durable and robust response that can prevent or control infections. Leveraging Viral Vector Technology Viral vectors serve as essential vehicles for delivering antigenic proteins or genetic material into target cells, triggering an immune response. Biotechnology companies have been exploring advanced strategies to optimize viral vector design, aiming to enhance immunogenicity and improve vaccine effectiveness. Vector Selection: The choice of viral vector plays a crucial role in determining immunogenicity. Different viruses have unique properties and characteristics that can impact immune responses. Biotechnology companies meticulously select viral vectors that possess the desired attributes, such as the ability to infect target cells efficiently and induce strong immune responses. Genetic Engineering: Advanced genetic engineering techniques are employed to modify viral vectors, tailoring them to specific vaccine requirements. By introducing specific antigenic proteins or genetic material, researchers can stimulate the immune system to mount a targeted response. This precise manipulation enhances the vaccine's ability to elicit a robust immune reaction. Immunomodulatory Elements: Biotechnology companies are incorporating immunomodulatory elements into viral vector designs. These elements can enhance the immune response by stimulating various components of the immune system, such as antigen-presenting cells and T cells. By activating and priming these immune cells, the vaccine can generate a more potent and sustained immune response. Adjuvants: Adjuvants are substances added to vaccines to enhance their immunogenicity. They stimulate and amplify the immune response, improving the va

The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for branded medicines pricing on Thursday (4 May). A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023 In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth. Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities. The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life sciences sector.

Three leading healthcare bodies in Scotland have called for action to reduce the environmental impact caused by medicine prescribing. The Academy of Medical Royal Colleges and Faculties in Scotland, Royal Pharmaceutical Society and the Royal College of General Practitioners Scotland have all urged policymakers to enable a more sustainable approach to prescribing. This includes prioritising the introduction of electronic prescribing across the NHS, introducing the requirement for an environmental impact in NHS medicines procurement and improving the availability of data about the environmental impact of medicines. "We call on Scottish government, including the chief medical officer, to enable the delivery of a realistic medicine approach to prescribing by developing a supportive infrastructure for green social prescribing across Scotland," said the healthcare professionals in a joint statement. They have called on the pharmaceutical industry to make information about the environmental impact of medicines readily available in a standardised data format.

The British Generic Manufacturers Association (BGMA) has elected Matthew Salzmann, UK Country Manager at Viatris, as its new Vice-Chair with immediate effect. He will replace the current chair of the BGMA, Diane DiGangi-Trench, who is the UK country head for Sandoz. Salzman, who is originally from Australia, has served approximately 1 billion patients worldwide last year as the UK Country Manager at Viatris, a global pharmaceutical company operating in 165 countries. In his role as BGMA Vice-Chair, Salzmann would focus on working in partnership with key stakeholders - the NHS, healthcare professionals, policy makers, clinical societies, patient associations, academia - to ensure access to affordable and sustainable medicines for patients and the NHS.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

Royal Pharmaceutical Society (RPS) Scotland has submitted its evidence to the Health, Social Care and Sport Committee's inquiry into 'Healthcare in remote and rural areas.' The Committee had sought views on what policies and actions would be most effective in addressing the issues people face when accessing healthcare in these areas. During the evidence session today (19 December), Laura Wilson, Director for RPS Scotland, highlighted the challenges faced by pharmacists and pharmacy in remote and rural areas, as well as provided some of the solutions for ensuring a sustainable pharmacy workforce. At present, people living in remote and rural areas of Scotland are required to travel to Glasgow or Aberdeen to undertake pharmacy training. Laura underscored the need to develop alternative education and training pathways, such as "grow your own" models, to support remote and rural areas to develop and retain local pharmacists.

Two weeks prior to the closing of the hub and spoke consultation, issues around patient safety, costs and competition as well as practicalities such as what to do with uncollected medicines were discussed in a webinar on hub and spoke dispensing on Wednesday (May 26). The webinar was organised by Sigma Pharmaceuticals in association with the National Pharmacy Association (NPA). NPA director of corporate affairs Gareth Jones chaired the event and was joined by Sigma's Hatul Shah and Raj Haria as well as NPA vice chair Nick Kaye and NPA head of advice and support services Jasmine Shah. Kaye said: "There are still many 'unknown unknowns' with hub and spoke and the jury's still out on any potential benefits. I have lots of reservations about cost and it worries me how efficient this is for the business and the long term sustainability for the sector as a whole. Above all we need to think about the patient at the centre of all this and the potential confusion for them." Jasmine Shah felt patient safety was going to be the key in regards to whether the spoke and the hub would hold the ultimate responsibility and "who is going to take the accountability as far as patient care goes". She added: "It is most important that GPhC standards and NHS requirement are both met in identifying all the risks associated with the arrangement with hub and spoke and ensuring that (patient safety) measures are in place. Everything that needs to be looked at is by putting the patient at heart of the arrangement and seeing what is the safest way for them to receive care from both spoke and hub."

The NHS is facing a range of long term challenges which needs to be countered with prevention, enhance personalised care and sustainable performance, health and social care secretary Sajid Javid said on Tuesday (March 8). In his speech on healthcare reform at the Royal College of Physicians in London, he said: "We face some long-term challenges: how to keep the NHS focused on delivery while futureproofing it for changing demographics and disease; how to meet rising patient expectations and address the injustices of widespread disparities; and how to deal with an unsustainable financial trajectory while backing the brilliant people who work in health and care." Javid emphasised on three key points for healthcare reform - prevention, personalisation and performance. He said, prevention is not just about building a 'national hospital service' but a true 'National Health Service'.

McKesson UK's CEO Toby Anderson has stepped down from the role with immediate effect after over three years with the company. Toby joined McKesson UK as CEO in September 2018 moving from health & beauty retailer A.S. Watson Group, where he spent 12 years in various roles. As CEO Asia and Eastern Europe, Toby was responsible for a rapidly growing business with more than 3,300 stores - including 1,500 pharmacies. Prior to that Toby spent 11 years in a number of senior roles with J. Sainsbury, the second largest grocery retailer in the UK, his last role being Head of Online. Dominik Meüser from AURELIUS Group said: "We are extremely grateful for the commitment Toby has demonstrated over the years to help us achieve the McKesson vision of becoming the UK's leading healthcare organisation. His leadership, during a period of great uncertainty, has given us the solid foundations we can now build on to deliver sustained success in the future.

The age at which people can buy tobacco in England should rise by one each year until it becomes a "smoke-free" society, a government-commissioned review recommended on Thursday (June 9). The minimum age today is 18. But the review by Javed Khan, former head of children's charity Barnardo's, advised raising it annually until eventually no one can buy tobacco products. His review recommends 15 interventions to help the government meet its national target to be smoke-free by 2030, including the promotion of vaping to help smokers quit. "Without immediate and sustained action, England will miss the smoke-free target by many years and most likely decades," said Khan. "A smoke-free society should be a social norm -- but to achieve this, we must do more to stop people taking up smoking, help those who already smoke and support those who are disproportionately impacted by smoking."

The Parliamentarians have called the government to urgently consider the short-term funding to stabilise the community pharmacy sector. 39 MPs and Peers from across the political spectrum have signed letters to the Health Secretary, Steve Barclay MP and raised their growing concern about the pressures facing England's community pharmacies and the risks this poses to patient care and safety. "Steve Barclay MP received correspondence from 23 Opposition MPs, with six Peers also signing a letter. Separately, 9 Conservative MPs also wrote to the Health Secretary and up to 10 others have signalled their intention to write to the relevant Minister," said the Pharmaceutical Services Negotiating Committee (PSNC). The Parliamentarians acknowledged that pharmacies have the potential to do more to support the NHS and they called for the government to urgently consider a commitment to working with the sector to create a fair and fit for purpose future funding model that ensures sustainability and properly funds pharmacies for what they do. All signatories also called for the introduction of a fairly-funded Pharmacy First service.

The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry. It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy. VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for the whole country. The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation. The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the highest contributions ever made before the pandemic.

If your loved one is suffering from anxiety, you'll likely be aware of how damaging the condition can be. Anxiety comes in many forms and can be triggered by an array of factors, but there are some simple steps to take if you want to improve the wellbeing of your family member - how can you best go about supporting a loved one with anxiety? What is anxiety? - Anxiety is mental state in which we feel highly worried, nervous, uneasy, or uncomfortable. While it's normal to feel anxious in certain situations and at notable points in our lives (this is linked to the 'fight or flight' instinct), it's important to address the problem if you feel that your anxiety is impacting your quality of life. What are the five major forms of anxiety? - The 5 most common forms of anxiety as diagnosed by medical professionals include generalised anxiety disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social phobia, also known as anxiety disorder. What causes anxiety problems? - Anxiety can be caused by a wide range of factors. We're more likely to become anxious when we're overworked, stressed, depressed, under financial pressure or physically or mentally unwell. It's also common to become anxious after traumatic events such as having to make medical negligence claim after sustaining a surgical based injury, losing a home or the death of a loved one.